Inhibrx Biosciences, Inc.
INBX
$82.96
$0.710.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 28.15% | -39.62% | |||
| Gross Profit | -36.09% | 43.14% | |||
| SG&A Expenses | -17.83% | 6.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.86% | -33.13% | |||
| Operating Income | -23.45% | 36.16% | |||
| Income Before Tax | -23.05% | 33.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.04% | 33.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.04% | 33.84% | |||
| EBIT | -23.45% | 36.16% | |||
| EBITDA | -24.32% | 36.70% | |||
| EPS Basic | -22.96% | 33.84% | |||
| Normalized Basic EPS | -22.97% | 33.85% | |||
| EPS Diluted | -23.08% | 33.84% | |||
| Normalized Diluted EPS | -22.97% | 33.85% | |||
| Average Basic Shares Outstanding | 0.06% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||